| sitravatinib (MGCD516) / BeiGene |
2014-000814-73: National Lung Matrix: Multi-drug Phase II trial in Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 620 | Europe | Palbociclib, Xalkori, Selumetinib, Docetaxel, Taxotere, Taxceus, Sitravatinib, AZD4547, AZD2014, PD 0332991, PF-02341066, AZD6244, ARRY 142886, MEDI4736, AZD5363, AZD9291, MGCD516, Tablet, Capsule, Concentrate for solution for infusion, Lyophilisate for solution for infusion, Xalkori, Docetaxel, Taxotere, Taxceus | University of Birmingham, AstraZeneca, Pfizer, Cancer Research UK | Metastatic or locally advanced non-small cell lung cancer (NSCLC), Commonest form of lung cancer, non-small cell lung cancer (NSCLC), Diseases [C] - Cancer [C04] | | | | |
NCT03680521: Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma |
|
|
| Completed | 2 | 25 | US | Sitravatinib, Nivolumab | Mirati Therapeutics Inc. | Clear Cell Renal Cell Carcinoma | 04/20 | 05/23 | | |
|
|
|
|
NCT03606174: A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma |
|
|
| Terminated | 2 | 260 | US | Sitravatinib, MGCD516, Nivolumab, Opdivo, Pembrolizumab, Keytruda, Enfortumab vedotin, Padcev | Mirati Therapeutics Inc. | Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter, Urothelial Carcinoma Urethra | 08/22 | 08/22 | | |
|
|
|
|
|
2021-002474-99: Sitravatinib and Tislelizumab with Metastatic UVEAL Melanoma with Liver Metastases Sitravatinib y Tislelizumab en Melanoma UVEAL metastásico con metástasis hepáticas |
|
|
| Not yet recruiting | 2 | 34 | Europe | Tislelizumab, Sitravatinib (malate formulation), Injection/infusion, Capsule | Grupo Español Multidisciplinar de Melanoma (GEM), Mirati, Beigene | Metastatic Uveal Melanoma with liver metastases Melanoma uveal metastásico con metástasis hepáticas, Metastatic Uveal Melanoma with liver metastases Melanoma uveal metastásico con metástasis hepáticas, Diseases [C] - Cancer [C04] | | | | |
BGB-900-2001-IIT, NCT04734262: A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) |
|
|
| Active, not recruiting | 2 | 98 | RoW | Sitravatinib, MGCD516, Tislelizumab, BGB-A317, Nab-paclitaxel, Nanoparticle albumin-bound paclitaxel | Fudan University | Metastatic Breast Cancer | 06/24 | 06/24 | | |
| Active, not recruiting | 2 | 29 | US | MGCD516, Sitravatinib | Matthew Ingham, Mirati Therapeutics Inc. | Liposarcoma, Metastatic Liposarcoma | 01/23 | 01/23 | | |
ITTACC, NCT05614453: Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy |
|
|
| Withdrawn | 2 | 57 | NA | Tislelizumab, BGB-A317, Sitravatinib, MGCD516 | Australia New Zealand Gynaecological Oncology Group, BeiGene | Metastatic Cervical Cancer | 06/23 | 06/23 | | |
BTC-BGB, NCT04727996: Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer |
|
|
| Active, not recruiting | 2 | 43 | RoW | Sitravatinib, MGCD516, Tislelizumab, BGB-A317 | Seoul National University Hospital, BeiGene | Advanced Biliary Tract Cancer | 07/23 | 12/24 | | |
BGB-900-2003-IIT, NCT05228496: A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLC |
|
|
| Active, not recruiting | 2 | 21 | RoW | Tislelizumab, Sitravatinib | Zhejiang Cancer Hospital | Lung Cancer, Small Cell | 07/23 | 06/25 | | |
NCT02664935: National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 2 | 423 | Europe | AZD4547, Vistusertib, AZD2014, Palbociclib, Crizotinib, Selumetinib, AZD6244, Docetaxel, AZD5363, Osimertinib, AZD9291, Durvalumab, MEDI4736, Sitravatinib, MGCD516, AZD6738 | University of Birmingham, Cancer Research UK, AstraZeneca, Pfizer, Experimental Cancer Medicine Centres, Mirati Therapeutics Inc. | Non-Small Cell Lung Cancer, Carcinoma, Squamous Cell, Adenocarcinoma | 09/24 | 09/24 | | |
|
|
| Not yet recruiting | 2 | 37 | NA | sitravatinib, tislelizumab | Beijing Cancer Hospital | Melanoma | 09/23 | 09/23 | | |
SITISVEAL, NCT05542342: Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. |
|
|
| Active, not recruiting | 2 | 16 | Europe | Tislelizumab, Sitravatinib Malate | Grupo Español Multidisciplinar de Melanoma, Mirati Therapeutics Inc., BeiGene | Uveal Melanoma | 12/23 | 05/24 | | |
STELLAR, NCT05176925: Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLC |
|
|
| Terminated | 2 | 5 | RoW | Tislelizumab, Sitravatinib | Fudan University | Non-small Cell Lung Cancer | 06/22 | 09/22 | | |
NCT05461794: Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma |
|
|
| Terminated | 2 | 96 | RoW | Sitravatinib, Tislelizumab, Docetaxel, Irinotecan | BeiGene | Esophageal Squamous Cell Carcinoma | 02/24 | 02/24 | | |
SNAPI, NCT04904302: Sitravatinib and Nivolumab for the Treatment of Metastatic or Advanced Clear Cell Renal Cell Cancer |
|
|
| Active, not recruiting | 2 | 88 | US | Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, Sitravatinib, MGCD516 | M.D. Anderson Cancer Center | Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8 | 01/25 | 01/25 | | |
NCT04925986: Sitravatinib Plus Pembrolizumab in Patients With Advanced Treatment-Naïve PD-L1+ Non-Squamous NSCLC |
|
|
| Terminated | 2 | 9 | US | Sitravatinib, IND 155305, Pembrolizumab, Keytruda | Sarah Goldberg, Mirati Therapeutics Inc. | Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Non-Small Cell Cancer AJCC v7, PD-L1 Gene Mutation, Advanced Treatment-Naïve PD-L1, Sitravatinib, Pembrolizumab | 06/23 | 10/23 | | |
NCT05419817: Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System |
|
|
| Withdrawn | 2 | 30 | NA | pembrolizumab, Keytruda®, Sitravatinib | Haider Mahdi, Mirati Therapeutics Inc. | Recurrent Endometrial Cancer, Solid Tumors | 07/25 | 12/26 | | |
NCT06029127: A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer |
|
|
| Recruiting | 2 | 100 | RoW | BGB-A445, Docetaxel, Ramucirumab, BGB-15025 | BeiGene | Non-Small Cell Lung Cancer | 01/26 | 05/26 | | |
ChiCTR2200065547: A phase II, open-label, single-arm, multi-center, prospective clinical study to investigate the efficacy and safety of tislelizumab combined with sitravatinib and docetaxel in patients with locally advanced or metastatic non-small cell lung cancer that progressed on or after chemotherapy and anti-PD-(L)1 antibody |
|
|
| Not yet recruiting | 2 | 43 | China | All patients will be treated with tislelizumab (200 mg intravenously every 3 weeks for up to 2 years) in combination with sitravatinib(70 mg once daily orally for up to 2 years) and docetaxel (60 mg/m2 intravenously every 3 weeks for 2 cycles). | West China Hospital of Sichuan University ; West China Hospital of Sichuan University, Partly funded by Beigene (Beijing) Biotechnology Co., LTD., and partly self-funded | non-small-cell lung cancer | | | | |
BGB-Sitra-2001-IIT, NCT05407519: A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection |
|
|
| Recruiting | 2 | 40 | RoW | Tislelizumab + Sitravatinib | Anhui Provincial Hospital, First Affiliated Hospital Xi'an Jiaotong University, First Affiliated Hospital of Guangxi Medical University, Henan Cancer Hospital | Hepatocellular Carcinoma | 06/26 | 06/26 | | |
BGB-900-104, NCT03941873: A Study to Investigate Sitravatinib as Monotherapy and in Combination With Tislelizumab in Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) or Gastric/Gastroesophageal Junction Cancer (GC/GEJC) |
|
|
| Completed | 1/2 | 111 | RoW | Sitravatinib, Sitravatinib plus Tislelizumab, Sitravatinib and tislelizumab | BeiGene | Carcinoma, Hepatocellular, Gastric/Gastroesophageal Junction Cancer | 03/23 | 03/23 | | |
|
